The Next-Generation Varicella Vaccine.
Setting a new standard in seroconversion protection with up to 98.2% seroconversion rates.
Engineered with advanced 2X Trehalose technology in a convenient Pre-Filled Syringe (PFS).

VZV has a secondary attack rate of up to 90% in susceptible household contacts, making it among the most contagious infectious diseases known to medicine.
Risks include secondary bacterial infections, pneumonia, and central nervous system manifestations including encephalitis and cerebellar ataxia.
Increased risk of severe morbidity in immunocompromised patients, pregnant women, and neonates, requiring heightened clinical vigilance and early intervention.
Patented in 158 countries;Double Trehalose acts as a superior cryoprotectant and thermo-stabilizer, ensuring the live attenuated virus maintains peak viability during manufacturing, storage and transport which enables a near 100% antigenic delivery to patients.
Clinically demonstrated in India’s largest clinical trial for varicella vaccine with a result of 98.2% seroconversion and 35.4 times higher GMFR providing superior immunogenicity and long-lasting protection against chickenpox disease.
Gelatin free vaccine minimizes the risk of severe allergic reactions associated with traditional vaccine stabilizers resulting in 0 Serious adverse events and 0% Breakthrough with 2 doses
The Pre-Filled Syringe (PFS) format eliminates reconstitution errors, reduces preparation time by 40%, and ensures precise dosage administration. Subcutaneous (SC) injection.